Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Bio-heart Biological Technology Co., Ltd. announces that its subsidiary, AngioCare, has reached an agreement with Terumo to waive exclusive distribution rights for its RDN products in the Greater China region, opening opportunities for new collaborations and expanded market reach. This strategic decision aims to leverage internal resources and enhance future commercialization efforts without adversely affecting the company’s operations.
For further insights into HK:2185 stock, check out TipRanks’ Stock Analysis page.